DKK 446.1
(-1.26%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 200.27 Million DKK | -54.84% |
2022 | 443.47 Million DKK | -43.68% |
2021 | 787.42 Million DKK | 557.02% |
2020 | 119.84 Million DKK | 39.75% |
2019 | 85.76 Million DKK | 0.0% |
2018 | - DKK | -100.0% |
2017 | 135.73 Million DKK | -59.15% |
2016 | 332.24 Million DKK | 6.16% |
2015 | 312.95 Million DKK | 14.98% |
2014 | 272.17 Million DKK | 0.0% |
2013 | - DKK | 0.0% |
2012 | - DKK | 0.0% |
2011 | - DKK | 0.0% |
2010 | - DKK | 0.0% |
2009 | - DKK | 0.0% |
2008 | - DKK | -100.0% |
2007 | 6.11 Million DKK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 389.99 Million DKK | 0.21% |
2024 Q1 | 389.18 Million DKK | 226.41% |
2023 FY | 200.27 Million DKK | -54.84% |
2023 Q2 | 116.86 Million DKK | -77.2% |
2023 Q3 | 116.05 Million DKK | -0.69% |
2023 Q4 | 119.23 Million DKK | 2.73% |
2023 Q1 | 512.55 Million DKK | 15.58% |
2022 Q1 | 790.19 Million DKK | 0.35% |
2022 Q4 | 443.47 Million DKK | -10.54% |
2022 Q2 | 485.42 Million DKK | -38.57% |
2022 Q3 | 495.72 Million DKK | 2.12% |
2022 FY | 443.47 Million DKK | -43.68% |
2021 Q2 | 143.77 Million DKK | 11.7% |
2021 Q3 | 142.03 Million DKK | -1.21% |
2021 Q1 | 128.71 Million DKK | 7.4% |
2021 Q4 | 787.42 Million DKK | 454.4% |
2021 FY | 787.42 Million DKK | 557.02% |
2020 Q3 | 133.5 Million DKK | -2.47% |
2020 Q1 | 101.2 Million DKK | 18.01% |
2020 Q2 | 136.88 Million DKK | 35.25% |
2020 FY | 119.84 Million DKK | 39.75% |
2020 Q4 | 119.84 Million DKK | -10.23% |
2019 Q2 | 3.33 Million DKK | -43.91% |
2019 FY | 85.76 Million DKK | 0.0% |
2019 Q1 | 5.94 Million DKK | 0.0% |
2019 Q3 | 68.49 Million DKK | 1953.06% |
2019 Q4 | 85.76 Million DKK | 25.22% |
2018 Q4 | - DKK | 0.0% |
2018 Q3 | - DKK | -100.0% |
2018 Q2 | 143.43 Million DKK | 6.92% |
2018 Q1 | 134.14 Million DKK | -1.17% |
2018 FY | - DKK | -100.0% |
2017 FY | 135.73 Million DKK | -59.15% |
2017 Q1 | 161.48 Million DKK | -51.39% |
2017 Q3 | 141.89 Million DKK | -2.84% |
2017 Q4 | 135.73 Million DKK | -4.34% |
2017 Q2 | 146.05 Million DKK | -9.56% |
2016 Q2 | 311.21 Million DKK | 3.08% |
2016 FY | 332.24 Million DKK | 6.16% |
2016 Q1 | 301.93 Million DKK | -3.52% |
2016 Q4 | 332.24 Million DKK | 6.44% |
2016 Q3 | 312.14 Million DKK | 0.3% |
2015 Q3 | 333.23 Million DKK | 10.67% |
2015 Q4 | 312.95 Million DKK | -6.09% |
2015 FY | 312.95 Million DKK | 14.98% |
2015 Q1 | 308.68 Million DKK | 13.42% |
2015 Q2 | 301.11 Million DKK | -2.45% |
2014 Q2 | - DKK | 0.0% |
2014 Q4 | 272.17 Million DKK | 0.0% |
2014 Q3 | - DKK | 0.0% |
2014 FY | 272.17 Million DKK | 0.0% |
2014 Q1 | - DKK | 0.0% |
2013 FY | - DKK | 0.0% |
2013 Q2 | - DKK | 0.0% |
2013 Q4 | - DKK | 0.0% |
2013 Q1 | - DKK | 0.0% |
2013 Q3 | - DKK | 0.0% |
2012 FY | - DKK | 0.0% |
2012 Q3 | - DKK | 0.0% |
2012 Q4 | - DKK | 0.0% |
2012 Q2 | - DKK | 0.0% |
2012 Q1 | - DKK | 0.0% |
2011 FY | - DKK | 0.0% |
2011 Q3 | - DKK | 0.0% |
2011 Q4 | - DKK | 0.0% |
2011 Q1 | - DKK | 0.0% |
2011 Q2 | - DKK | 0.0% |
2010 Q4 | - DKK | 0.0% |
2010 FY | - DKK | 0.0% |
2009 FY | - DKK | 0.0% |
2008 FY | - DKK | -100.0% |
2007 FY | 6.11 Million DKK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
ALK-Abelló A/S | 765 Million DKK | 73.82% |
Bavarian Nordic A/S | 145.3 Million DKK | -37.834% |
Genmab A/S | 770 Million DKK | 73.99% |
Gubra A/S | 71.43 Million DKK | -180.36% |
Novo Nordisk A/S | 27 Billion DKK | 99.258% |
Orphazyme A/S | - DKK | -Infinity% |
Pharma Equity Group A/S | 30.22 Million DKK | -562.701% |